NVS Company Profile and Key Details

Short-term trend indicators are bearishly aligned (SMA20 3.97%, SMA50 11.52%, SMA200 27.9%). The stock’s 14-day RSI is 70.7 (overbought), while the ATR of 2.64 points to moderate volatility. The stock remains sitting in the mid-range of its 52-week band, trading -1.49% below its high and over 69.38% above its low. Average 10-day trading volume of 1.58 million shares is below the 3-month average of 1.86 million, indicating normal recent market interest.

Novartis AG generated EPS of $7.19 over the past year. Five-year average earnings growth is 15.38%. Wall Street analysts project EPS growth of 6.19% annually over the next five years. The latest quarter delivered EPS of $2.41. The next quarter is forecast at $2.11. Next year's EPS is expected at $8.35. Analyst sentiment is bearish. Analyst rating data shows there are 1 Strong Buy ratings, 0 Buy ratings, 0 Hold ratings, 1 Sell rating and 0 Strong Sell ratings. Price targets range from $170.00 to $118.00. The high target offers 6.04% upside. The low target suggests -26.39% downside. The mean target is $144.00. This offers -10.17% upside. Novartis AG earnings surprise history is a mixed track record. The quarter that ended July 21, 2026, missed forecasts by 9.55%. The prior quarter beat by -5.69%. Over the last six quarters, Apple has recorded several small beats. These include 7.55% in April 29, 2025.

Novartis AG has 1.90 billion shares outstanding. The public float is 1.86 billion shares, elevated short interest at 0.30% of float. This equals 5.71 million shares. The short ratio is 2.66 days. Institutional investors hold 7.68% of the float. Insiders own 0.0%.

Novartis AG last paid a dividend of 4.74 per share, this equals a trailing yield of roughly 3.37%. Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $208.98. This means the shares are trading below this model’s fair value.

Novartis AG (NYSE:NVS) closed at $156.24 USD, losing -$4.07 (-2.54%) from the previous close of $160.31. The stock is currently mid-range between its 52-week high and low $121.57 and $170.46. With a market capitalization of about $296.97 billion, Novartis AG is classified as a mega-cap and shows lower-than-market volatility (beta ~0.46). Key stats such as the average daily volume over the past year has been around 1.88 million shares, in line with its 52-week average. Headquartered in Basel, BS, Novartis AG operates in the Healthcare sector and the Drug Manufacturers - General industry. Led by CEO Vas Narasimhan, the company employs approximately 75,267 people and listed since November 07, 1996. Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products.

Novartis AG trades at a P/E ratio of 23.52, slightly below the S&P 500 average, with a price-to-sales ratio of 5.35 and a price-to-book ratio of 7.18 trading at moderately above to book value. The P/FCF stands at 18.82, also above market averages.

Novartis AG (NYSE:NVS) shares are flat 4.14% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Novartis AG trading at a premium to the broader market with a P/E of 23.52. Analyst sentiment is bullish, with the majority of ratings in Overweight territory and a mean price target of $121.44, suggesting -24.25% downside. Our AI forecast model points to short-term weakness (-3.97% over two weeks), a medium-term fall (-30.99% over three months), and a longer-term gain (10.67% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Novartis AG stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -3.97%, with price expected at $153.94 by September 02, 2026, within a range of $150.82 to $156.87 3-Month Outlook: Projected fall of -30.99%, reaching $110.63 by November 17, 2026, with a range of $104.12 to $115.99. 1-Year Outlook: Projected gain of 10.67%, with price at $177.42 by August 19, 2027, within a range of $174.34 to $181.10.